'Sae differences' presentation slideshows

Ranibizumab and bevacizumab for neovascular armd * The CATT research group*

Ranibizumab and bevacizumab for neovascular armd * The CATT research group*. Juan G. Santiago, MD Valley Retina Institute, P.A. May 6, 2011. Background. In 2005, clinical trials have established the efficacy of ranibizumab ( Lucentis ) for the treatment of neovascular AMD.

605 views • 42 slides